[2 consecutive North China Pharmaceuticals: Injectable streptomycin sulfate sales revenue is small] On October 9th, North China Pharmaceuticals (600812.SH) announced that the company's stock had a cumulative deviation of 20% from the closing price increase for three consecutive trading days on September 30, October 8, and October 9, 2026, which was an abnormal fluctuation in stock trading. The company is concerned that the market has recently paid high attention to hot concepts related to "plague". After verification, the company's instructions for Streptomycin Sulfate for Injection show that its indications include the treatment of tularemia alone, or in combination with other antibacterial drugs for the treatment of plague, inguinal granuloma, brucellosis, rat-bite fever, etc. This product is a traditional antibiotic variety of the company. The sales revenue of this product in 2025 and January-June 2026 will be small and will not have a significant impact on the company's overall operating performance. Except for the above, the Company has not found any other media reports or market rumors that may have a significant impact on the trading price of the Company's shares.